On Monday, Shares of St. Jude Medical, Inc. (NYSE:STJ), gained 2.20% to $65.39. 2.67 million shares of the company were exchanged.
St. Jude Medical, Inc. (STJ), a global medical device company, recently declared the company has received CE Mark approval for the HeartMate 3™ Left Ventricular Assist System (LVAS), a cardiac support option for advanced heart failure patients who are awaiting transplantation, are not candidates for heart transplantation, or are in myocardial recovery.
The HeartMate 3 system is the first commercially approved centrifugal-flow left ventricular assist device (LVAD) utilizing Full MagLev™ (fully magnetically-levitated) technology, which allows the device’s rotor to be “suspended” by magnetic forces. This design aims to reduce trauma to blood passing through the pump and improve outcomes for patients.
The device is implanted above the diaphragm, right away next to the native heart, and is attached to the aorta leaving natural circulation in place while providing all of the energy necessary to propel blood throughout the body.
St. Jude Medical, Inc., together with its auxiliaries, develops, manufactures and distributes cardiovascular medical devices for cardiac rhythm administration, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies.
Shares of International Business Machines Corp. (NYSE:IBM), declined -0.82% to $151.14, during its last trading session.
IBM (NYSE:IBM) declared new support to manage high volume global payments in all types of currency. Already supporting the transmission of 30 percent of financial messages across the SWIFT network, IBM Financial Transaction Manager (FTM), now also enables banks to converge their SWIFT payment operations onto one payment hub to improve operational efficiency and speed transactions while delivering a seamless banking experience for clients.
The Society for Worldwide Interbank Financial Telecommunication (SWIFT) network enables financial institutions worldwide to send and receive information about financial transactions in a secure, standardized and reliable environment. For banks around the world, financial transaction processing is complex, spread across multiple platforms and often dealing with many different currencies and transaction types. Banks need a foundation to manage all their payment operations on a single advanced platform to reduce costs, enhance transparency and simplify payments procedures. With declaration, FTM expands delivery of multi-payment, multi-currency platform which can deliver the speed, security and simplicity banks are looking for to build new services and deliver both batch and real time solutions to their clients.
International Business Machines Corporation provides information technology (IT) products and services worldwide. The company’s Global Technology Services segment provides IT infrastructure and business process services, such as outsourcing, processing, integrated technology, cloud, and technology support.
At the end of Monday’s trade, Shares of Celsion Corporation (NASDAQ:CLSN), inclined 4.35% to $1.92.
Celsion Corporation (CLSN), an oncology drug development company, stated data from a large preclinical study of the Company’s GEN-1 IL-12 immunotherapy in combination with Avastin® and Doxil® for the treatment of ovarian cancer. Results from the comprehensive studies confirmed remarkable initial GEN-1 + Avastin findings and show convincingly that GEN-1 when combined with Avastin® and Doxil®, standard of care for platinum resistant patients, demonstrated a greater than 98% reduction in tumor burden when contrast to the untreated control group. The findings represent a statistically noteworthy reduction in tumor burden and disease progression when contrast to the combination of Avastin® and Doxil® in a SKOV3 human cell line implanted into immunocompromised (nude) mice.
Analysis of serum chemistry and hematology suggested no overt toxicities associated with the combined treatments. The preclinical data are consistent with the mechanism of action for GEN-1, which exhibits certain anti-angiogenic properties in addition to its well-characterized immunomodulatory activities.
GEN-1 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein. GEN-1 has already demonstrated encouraging safety and efficacy clinical data in combination with PEGylated doxorubicin (Doxil®) in patients with platinum-resistant ovarian cancer, with a clinical response rate (CR+PD+SD) of 86% at the highest GEN-1 dose cohort. GEN-1 has also produced encouraging data in combination with Avastin® alone in earlier preclinical studies in a model of ovarian cancer, leading to a noteworthy reduction in tumor burden and disease progression. Additionally, the data show that GEN-1 treatment alone resulted in anti-tumor activity that was as good as or better than Avastin® treatment alone.
Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
